证券日报网讯12月19日晚间，健之佳（605266）发布公告称，截至本公告披露日，公司不存在逾期对外 担保。 ...

| 对外担保逾期的累计金额（万元） | 0 | | --- | --- | | 截至本公告日上市公司及其控股 子公司对外担保总额（万元） | 194,357.40 | | 对外担保总额占上市公司最近一 期经审计净资产的比例（%） | 69.48 | | 特别风险提示 | 对外担保总额（含本次）超过上市公司最近一 | | | 期经审计净资产 50% | | | □对外担保总额（含本次）超过上市公司最近 | | | 一期经审计净资产 100% | | | □对合并报表外单位担保总额（含本次）达到 | | | 或超过最近一期经审计净资产 30% | | | □本次对资产负债率超过 70%的单位提供担保 | | 其他风险提示 | 无 | 证券代码：605266 证券简称：健之佳 公告编号：2025-057 健之佳医药连锁集团股份有限公司 关于为子公司提供担保的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 担保对象及基本情况 | | 被担保人名称 | | | 广西健之佳勤康医药销售有限公司 | | --- ...

截至9月30日，健之佳股东户数1.51万，较上期减少0.04%；人均流通股10240股，较上期增加0.04%。 2025年1月-9月，健之佳实现营业收入65.49亿元，同比减少2.77%；归母净利润1.01亿元，同比减少 0.22%。 分红方面，健之佳A股上市后累计派现7.15亿元。近三年，累计派现4.73亿元。 12月19日，健之佳盘中下跌2.03%，截至09:38，报19.76元/股，成交1422.32万元，换手率0.46%，总市 值30.54亿元。 资金流向方面，主力资金净流入14.74万元，大单买入154.34万元，占比10.85%，卖出139.60万元，占比 9.81%。 健之佳今年以来股价跌10.24%，近5个交易日涨2.60%，近20日涨0.51%，近60日跌8.18%。 资料显示，健之佳医药连锁集团股份有限公司位于云南省昆明市盘龙区联盟街道旗营街10号，成立日期 2004年9月27日，上市日期2020年12月1日，公司主营业务涉及药品、保健食品、个人护理品、家庭健康 用品、便利食品、日用消耗品等健康产品的连锁零售业务,并提供相关专业服务。主营业务收入构成 为：处方、非处方合计(中西成药)72. ...

（编辑 丛可心） 证券日报网讯 12月17日，健之佳在互动平台回答投资者提问时表示，公司以顾客需求为核心，聚焦主 业，长期专注于差异化定位的药品零售、便利零售行业，持续强化核心竞争力。面对政策影响、医药消 费低迷、行业短期压力和中期转型挑战，公司迅速调整短期经营策略，坚决转型，聚焦存量门店效率以 争取市场份额。非常感谢投资者对公司的关注以及提出的转型建议，一方面对跨行业、跨界进入不熟 悉、公司尚未具备优势的竞争性领域，公司持开放但审慎的态度评估风险及自身能力潜力，另一方面， 坚决推进转型工作，以提升店效、人效。 ...

证券代码：605266 证券简称：健之佳 公告编号：2025-056 健之佳医药连锁集团股份有限公司 关于为子公司提供担保的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 担保对象及基本情况 | 担 保 | 对 | 被担保人名称 本次担保金额 | 12,500 | 万元 | 云南健之佳连锁健康药房有限公司 | | --- | --- | --- | --- | --- | --- | | 象一 | | 实际为其提供的担保余额 | 62,859.45 | 万元 | | | | | 是否在前期预计额度内 | 是 | □否 | □不适用：_________ | | | | 本次担保是否有反担保 | □是 | 否 | □不适用：_________ | | 担 保 | 对 | 被担保人名称 本次担保金额 | 3,000 | 云南之佳便利店有限公司 万元 万元 | | | | | 实际为其提供的担保余额 | 3,814.99 | | | | 象二 | | | | | | | | | 是否在前期预计额度内 | ...

Core Viewpoint - The stock price of Jianzhijia has shown a slight increase of 2.04% on November 26, 2023, with a current price of 20.52 CNY per share, despite a year-to-date decline of 6.79% [1] Company Overview - Jianzhijia Pharmaceutical Chain Group Co., Ltd. is located in Kunming, Yunnan Province, and was established on September 27, 2004. The company was listed on December 1, 2020. Its main business involves the retail of health products, including pharmaceuticals, health foods, personal care products, and daily consumables [1] - The revenue composition of Jianzhijia includes: prescription and non-prescription drugs (72.60%), with non-prescription drugs at 39.64% and prescription drugs at 32.96%. Other segments include medical devices (7.44%), other (5.52%), convenience products (5.05%), health foods (4.84%), traditional Chinese medicine (3.28%), personal care products (1.18%), and health check services (0.09%) [1] Financial Performance - For the period from January to September 2025, Jianzhijia reported a revenue of 6.549 billion CNY, a year-on-year decrease of 2.77%. The net profit attributable to the parent company was 101 million CNY, reflecting a slight decrease of 0.22% year-on-year [2] - Since its A-share listing, Jianzhijia has distributed a total of 715 million CNY in dividends, with 473 million CNY distributed over the past three years [3] Shareholder Information - As of September 30, 2025, Jianzhijia had 15,100 shareholders, a slight decrease of 0.04% from the previous period. The average circulating shares per person increased by 0.04% to 10,240 shares [2] - Among the top ten circulating shareholders, Rongtong Health Industry Flexible Allocation Mixed A/B holds 7.1 million shares, remaining unchanged from the previous period. Meanwhile, Guangfa Innovation Upgrade Mixed has exited the top ten list [3]

Core Viewpoint - The article highlights the rising demand for flu vaccines, antiviral medications, and related testing services due to the increasing flu activity across various regions in China as winter approaches [2][6][8]. Group 1: Flu Vaccine and Antiviral Demand - The flu season is expected to drive significant growth in demand for flu vaccines, respiratory testing, and antiviral medications [2][6]. - Recent data indicates a notable increase in flu vaccine appointments and antiviral drug purchases, with some areas reporting over 500% growth in the number of buyers for antiviral medications [7][8]. - Specific antiviral drugs like Marbofloxacin have seen a remarkable increase in demand, with purchases rising over 600% in recent weeks [7]. Group 2: Market Opportunities - Analysts suggest that the current flu outbreak may lead to heightened public and market interest, creating investment opportunities in flu vaccines, virus testing, and cold medications [8]. - The demand for flu-related products is expected to surge, particularly for antiviral medications such as Oseltamivir and Marbofloxacin, as well as traditional Chinese medicine for flu treatment [8]. - The increase in flu cases is likely to boost the need for diagnostic testing, both in hospitals and for home monitoring, indicating a potential market expansion for testing products [8].

证券日报网讯健之佳（605266）11月19日在互动平台回答投资者提问时表示，公司在定期报告中披露公 司股东相关信息，敬请查阅。除定期报告要求外，公司未披露股东人数或持股情况，考虑到信息披露的 公平性原则，公司不宜向单个股东提供上述信息。 ...

Market Overview - The pharmaceutical commercial sector experienced a decline of 0.92% on November 18, with Yao Yigou leading the drop [1] - The Shanghai Composite Index closed at 3939.81, down 0.81%, while the Shenzhen Component Index closed at 13080.49, down 0.92% [1] Stock Performance - Notable gainers included: - Ren Da Medical (603108) with a closing price of 15.97, up 2.90% and a trading volume of 278,200 shares, totaling 442 million yuan [1] - People's Tongtai (600829) with a closing price of 17.72, up 6.49% and a trading volume of 1,148,700 shares, totaling 1.902 billion yuan [1] - Major decliners included: - Yao Yigou (300937) with a closing price of 33.95, down 6.37% and a trading volume of 115,000 shares, totaling 396 million yuan [2] - Luhua Pharmaceutical (002788) with a closing price of 10.29, down 5.86% and a trading volume of 467,300 shares, totaling 489 million yuan [2] Capital Flow - The pharmaceutical commercial sector saw a net outflow of 706 million yuan from institutional investors, while retail investors contributed a net inflow of 705 million yuan [2] - The overall capital flow indicates a mixed sentiment, with institutional investors withdrawing while retail investors remained active [2] Individual Stock Capital Flow - Ren Da Medical (603108) had a net inflow of 49.2 million yuan from institutional investors, while retail investors saw a net outflow of 65.5 million yuan [3] - Yao Yigou (300937) experienced a significant net outflow of 560.4 million yuan from institutional investors [3] - The data reflects varying levels of investor confidence across different stocks within the sector [3]

Group 1 - The number of listed companies disclosing data is steadily increasing, indicating the maturation of China's nutrition and health industry [1] - Jiyuan Group shows considerable growth potential for HMB [1] - Minsheng Health is promoting stable growth in its mineral business through the synergy of online and offline channels [1] Group 2 - The third-quarter reports of seven major listed chain pharmacies have been released, revealing that Dazhenlin, Yifeng Pharmacy, Shuyapingmin, and Huaren Health achieved both revenue and net profit growth, while Laobaixing, Yixintang, and Jianzhijia experienced declines in both metrics [1] - The overall expansion speed of chain pharmacies has noticeably slowed, with a shift in focus from scale expansion to quality improvement and efficiency [1] - Specific performance data for the seven listed chain pharmacies for the first three quarters of the year includes: - Dazhenlin: Revenue of 20.068 billion, up 1.71%; Net profit of 1.081 billion, up 25.97% - Yifeng Pharmacy: Revenue of 17.286 billion, up 0.39%; Net profit of 1.225 billion, up 10.27% - Laobaixing: Revenue of 16.07 billion, down 1%; Net profit of 529 million, down 16.11% - Yixintang: Revenue of 13.001 billion, down 4.33%; Net profit of 269 million, down 8.17% - Jianzhijia: Revenue of 6.549 billion, down 2.80%; Net profit of 101 million, down 0.20% - Shuyapingmin: Revenue of 7.446 billion, up 5.19%; Net profit of 1.09 billion, up 927.37% - Huaren Health: Revenue of 3.892 billion, up 19.06%; Net profit of 157 million, up 45.21% [1] Group 3 - The trademark dispute involving Tongrentang is expected to come to an end as the acquisition of Tianjin Tongrentang Group's shares by Beijing Tongrentang Group has entered the acceptance stage, allowing Beijing Tongrentang to hold 60% of Tianjin Tongrentang [2] Group 4 - Six stores of Laobaixing in Loudi, Hunan Province were penalized for insurance fraud, where they switched health products for insurance-covered medications, leading to a fine and the revocation of their insurance service agreements [3]